Close Menu
April 27, 2021
Sponsored by
Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Genome Webinar

Medical Oncologist,
Gustave Roussy Institute

Scientific Project Manager,
Biognosys 

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Recent advances in mass spectrometry-based proteomics have fostered a more precise, deep, and more functional look into clinical phenotypes. Going beyond traditional genomics, proteomics enables more relevant, quantitative, and informative understanding of diseases and treatments.

Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, will share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

They will discuss the results of a joint project in which serum from a cohort of patients infected with COVID-19 was submitted for analysis using the Biognosys HRM discovery proteomics platform. They will share details of proteomic profiles associated with clinical outcome, comorbidities, and the response to anti-IL6 treatment, which provide a comprehensive picture of the potential of using next-generation proteomics to enhance personalized medicine. 

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by
Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.